The government is connecting people to a new and innovative treatment for those living with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease.
Ontario is the first Canadian jurisdiction to cover the new treatment, Albrioza, under the province’s publicly funded drug program.
News Release; https://news.ontario.ca/en/release/1003213/ontario-first-in-canada-to-provide-coverage-for-new-als-treatment